The Other Side of TNF-targeted Therapy of Patients with Rheumatoid Arthritis
Overview
Overview
Journal
Curr Rheumatol Rep
Publisher
Current Science
Specialty
Rheumatology
Date
2001 Mar 20
PMID
11177764
Citations
1
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
The Japanese experience with biologic therapies for rheumatoid arthritis.
Takeuchi T, Kameda H Nat Rev Rheumatol. 2010; 6(11):644-52.
PMID: 20877307 DOI: 10.1038/nrrheum.2010.154.
References
1.
Feldmann M, Brennan F, Maini R
. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996; 14:397-440.
DOI: 10.1146/annurev.immunol.14.1.397.
View
2.
Stephens S, Emtage S, Vetterlein O, Chaplin L, Bebbington C, Nesbitt A
. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology. 1995; 85(4):668-74.
PMC: 1383798.
View
3.
Moreland L, Baumgartner S, Schiff M, Tindall E, Fleischmann R, Weaver A
. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997; 337(3):141-7.
DOI: 10.1056/NEJM199707173370301.
View
4.
Maini R, Breedveld F, Kalden J, Smolen J, Davis D, Macfarlane J
. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998; 41(9):1552-63.
DOI: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W.
View
5.
Rankin E, Choy E, Kassimos D, Kingsley G, Sopwith A, Isenberg D
. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol. 1995; 34(4):334-42.
DOI: 10.1093/rheumatology/34.4.334.
View